CN100367930C - 可自发分散的n-苯甲酰基-星形孢菌素组合物 - Google Patents

可自发分散的n-苯甲酰基-星形孢菌素组合物 Download PDF

Info

Publication number
CN100367930C
CN100367930C CNB008038244A CN00803824A CN100367930C CN 100367930 C CN100367930 C CN 100367930C CN B008038244 A CNB008038244 A CN B008038244A CN 00803824 A CN00803824 A CN 00803824A CN 100367930 C CN100367930 C CN 100367930C
Authority
CN
China
Prior art keywords
benzoyl
staurosporine
surfactant
bioavailability
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB008038244A
Other languages
English (en)
Chinese (zh)
Other versions
CN1339963A (zh
Inventor
G·P·玛休斯
B·哈伯林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10847896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100367930(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1339963A publication Critical patent/CN1339963A/zh
Application granted granted Critical
Publication of CN100367930C publication Critical patent/CN100367930C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB008038244A 1999-02-16 2000-02-14 可自发分散的n-苯甲酰基-星形孢菌素组合物 Expired - Lifetime CN100367930C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9903547.9 1999-02-16
GBGB9903547.9A GB9903547D0 (en) 1999-02-16 1999-02-16 Organic compounds

Publications (2)

Publication Number Publication Date
CN1339963A CN1339963A (zh) 2002-03-13
CN100367930C true CN100367930C (zh) 2008-02-13

Family

ID=10847896

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008038244A Expired - Lifetime CN100367930C (zh) 1999-02-16 2000-02-14 可自发分散的n-苯甲酰基-星形孢菌素组合物

Country Status (34)

Country Link
US (3) US20020061873A1 (https=)
EP (1) EP1152750B1 (https=)
JP (2) JP5057610B2 (https=)
KR (2) KR100880859B1 (https=)
CN (1) CN100367930C (https=)
AR (2) AR022589A1 (https=)
AT (1) ATE430554T1 (https=)
AU (1) AU765776B2 (https=)
BR (1) BRPI0008228B8 (https=)
CA (1) CA2362277C (https=)
CL (1) CL2009001682A1 (https=)
CZ (1) CZ303979B6 (https=)
DE (1) DE60042151D1 (https=)
DK (1) DK1152750T3 (https=)
EC (1) ECSP083351A (https=)
ES (1) ES2326783T3 (https=)
GB (1) GB9903547D0 (https=)
HK (1) HK1045807B (https=)
HU (1) HUP0105364A3 (https=)
ID (1) ID30504A (https=)
IL (3) IL144512A0 (https=)
MY (1) MY128362A (https=)
NO (1) NO331232B1 (https=)
NZ (1) NZ513529A (https=)
PE (1) PE20001499A1 (https=)
PL (1) PL198330B1 (https=)
PT (1) PT1152750E (https=)
RU (1) RU2266121C2 (https=)
SI (1) SI1152750T1 (https=)
SK (1) SK286967B6 (https=)
TR (1) TR200102385T2 (https=)
TW (1) TWI240636B (https=)
WO (1) WO2000048571A1 (https=)
ZA (1) ZA200106677B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US7795246B2 (en) 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
PT1372611E (pt) * 2001-03-26 2006-08-31 Novartis Ag Composicao farmaceutica compreendendo uma estaurosporina francamente soluvel em agua, um tensioactivo et um polimero soluvel em agua
CA2444867C (en) 2001-05-16 2010-08-17 Novartis Ag Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
DE60213842T2 (de) * 2001-10-30 2007-09-06 Novartis Ag Staurosporin-derivate als hemmer der flt3-rezeptor-tyrosinkinase-wirkung
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
EP1531793A1 (en) * 2002-07-23 2005-05-25 Novartis AG Ophtalmic ointment composition comprising a drug, an ointment base and a solubiling/dispersing agent
US7842791B2 (en) 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
GB0419159D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
GT200500310A (es) * 2004-11-19 2006-06-19 Compuestos organicos
JP5546860B2 (ja) * 2006-08-16 2014-07-09 ノバルティス アーゲー 高結晶性治療化合物の固体分散体を製造するための方法
FR2918566B1 (fr) 2007-07-11 2009-10-09 Pierre Fabre Medicament Sa Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
US20090155352A1 (en) * 2007-11-20 2009-06-18 Cephalon, Inc. Microemulsion containing indolocarbazole compound and dosage forms containing the same
EP2229936B1 (en) * 2009-03-09 2015-05-06 PharmaSol GmbH Nanonized testosterone formulations for improved bioavailability
WO2011000811A2 (en) * 2009-06-30 2011-01-06 Novartis Ag Organic compounds
US20120322776A1 (en) * 2009-12-22 2012-12-20 Leo Pharma A/S Cutaneous composition comprising vitamin d analogue and a mixture of solvent and surfactants
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
US9387446B2 (en) * 2011-09-22 2016-07-12 Ariel-University Research And Development Company Ltd. Emulsions and methods of making emulsions
RU2742650C2 (ru) * 2015-12-09 2021-02-09 Фосфейдженикс Лимитед Фармацевтический состав
MX383940B (es) 2015-12-09 2025-03-14 Phosphagenics Ltd Formulación farmacéutica que contiene tocol fosfato.
IL267006B2 (en) 2016-12-21 2024-11-01 Phosphagenics Ltd Process for phosphorylation of a complex alcohol with p4o10 at high temperatures, and products thereof
WO2021097256A1 (en) 2019-11-14 2021-05-20 Cohbar, Inc. Cxcr4 antagonist peptides

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
DE4418115A1 (de) * 1993-05-27 1994-12-01 Sandoz Ag Galenische Formulierungen
EP0657164A1 (en) * 1993-12-11 1995-06-14 Ciba-Geigy Ag Pharmaceutical compositions containing staurosphorine derivatives
US5658898A (en) * 1994-11-09 1997-08-19 Ciba Geigy Corporation Intravenous solutions for a derivative of staurosporine
US5726164A (en) * 1995-03-21 1998-03-10 Novartis Corporation Nanosuspensions for intravenous administration

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4735939A (en) 1987-02-27 1988-04-05 The Dow Chemical Company Insecticidal activity of staurosporine
DE3824034C1 (https=) * 1988-07-15 1989-09-14 Gustav 7290 Freudenstadt De Memminger
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
AU668509B2 (en) 1991-04-19 1996-05-09 Affinity Biotech, Inc. Convertible microemulsion formulations
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
US6306421B1 (en) * 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
PT589843E (pt) * 1992-09-25 2002-04-29 Novartis Ag Composicoes farmaceuticas contendo ciclosporinas
US5981568A (en) * 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5639474A (en) 1993-07-01 1997-06-17 Hanmi Pharm. Ind., Ltd. Cyclosporin soft capsule composition
JPH09510182A (ja) 1993-11-17 1997-10-14 エルディーエス・テクノロジーズ・インコーポレーテッド カプセル封入されたドラッグデリバリー用透明液
WO1995022331A1 (en) 1994-02-18 1995-08-24 Cephalon, Inc. Aqueous indolocarbazole solutions
WO1995032975A1 (en) * 1994-06-01 1995-12-07 Ciba-Geigy Ag Indolocarbazole derivatives for sensitizing multidrug-resistant cells to antitumor agents
IL129547A (en) * 1994-10-26 2001-01-11 Novartis Ag Pharmaceutical compositions comprising a macrolide and an acid
GB2308545B (en) 1994-10-26 1999-06-02 Novartis Ag Pharmaceutical microemulsion preconcentrates
WO1998013032A1 (en) 1996-09-27 1998-04-02 Trega Biosciences, Inc. Compositions of therapeutic agents suitable for oral administration
DE19641672A1 (de) 1996-10-10 1998-04-16 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen auf der Basis von ethylenoxidfreien und propylenoxidfreien Emulgatoren zur Herstellung von Mikroemulsionsgelen
US5827522A (en) 1996-10-30 1998-10-27 Troy Corporation Microemulsion and method
NZ314060A (en) 1997-01-13 1997-08-22 Bernard Charles Sherman Pharmaceutical microemulsion preconcentrate comprising cyclosporin dissolved in a solvent system comprising hydrophobic solvent(s) and surfactant(s)
SK285019B6 (sk) * 1997-01-30 2006-04-06 Novartis Ag Tvrdá želatínová tobolka
ATE265847T1 (de) 1997-07-29 2004-05-15 Upjohn Co Selbstemulgierbare formulierung enthaltend lipophile verbindungen
PL192080B1 (pl) 1997-07-29 2006-08-31 Upjohn Co Kompozycja farmaceutyczna zawierająca związek piranonowy
US6346511B1 (en) 1997-09-08 2002-02-12 Panacea Biotec Limited Pharmaceutical composition comprising cyclosporin
US6979456B1 (en) * 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
GB9814527D0 (en) * 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
AR013276A1 (es) 1998-07-31 2000-12-13 Panacea Biotec Ltd Composicion de ciclosporina transparente
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
DE4418115A1 (de) * 1993-05-27 1994-12-01 Sandoz Ag Galenische Formulierungen
EP0657164A1 (en) * 1993-12-11 1995-06-14 Ciba-Geigy Ag Pharmaceutical compositions containing staurosphorine derivatives
US5658898A (en) * 1994-11-09 1997-08-19 Ciba Geigy Corporation Intravenous solutions for a derivative of staurosporine
US5726164A (en) * 1995-03-21 1998-03-10 Novartis Corporation Nanosuspensions for intravenous administration

Also Published As

Publication number Publication date
TWI240636B (en) 2005-10-01
ES2326783T3 (es) 2009-10-20
NO331232B1 (no) 2011-11-07
TR200102385T2 (tr) 2002-09-23
GB9903547D0 (en) 1999-04-07
PL198330B1 (pl) 2008-06-30
JP5057610B2 (ja) 2012-10-24
US20080070897A1 (en) 2008-03-20
ATE430554T1 (de) 2009-05-15
ZA200106677B (en) 2003-01-14
IL144512A (en) 2011-03-31
ID30504A (id) 2001-12-13
WO2000048571A1 (en) 2000-08-24
SK11722001A3 (sk) 2001-12-03
DE60042151D1 (de) 2009-06-18
CZ20012931A3 (cs) 2001-11-14
KR100880859B1 (ko) 2009-01-30
ECSP083351A (es) 2008-08-29
HUP0105364A3 (en) 2003-02-28
US20020061873A1 (en) 2002-05-23
BRPI0008228B8 (pt) 2021-05-25
JP2012111763A (ja) 2012-06-14
BR0008228A (pt) 2001-10-30
US8722664B2 (en) 2014-05-13
MY128362A (en) 2007-01-31
IL144512A0 (en) 2002-05-23
NO20013964L (no) 2001-10-15
KR20080064914A (ko) 2008-07-09
AU3154200A (en) 2000-09-04
AU765776B2 (en) 2003-10-02
US8575147B2 (en) 2013-11-05
CL2009001682A1 (es) 2010-07-23
CZ303979B6 (cs) 2013-07-31
AR022589A1 (es) 2002-09-04
PL350556A1 (en) 2002-12-16
NO20013964D0 (no) 2001-08-15
SK286967B6 (sk) 2009-08-06
DK1152750T3 (da) 2009-08-24
EP1152750A1 (en) 2001-11-14
CA2362277C (en) 2010-03-30
CA2362277A1 (en) 2000-08-24
HK1045807B (zh) 2008-12-05
PT1152750E (pt) 2009-08-07
SI1152750T1 (sl) 2009-10-31
EP1152750B1 (en) 2009-05-06
RU2266121C2 (ru) 2005-12-20
HK1045807A1 (zh) 2002-12-13
CN1339963A (zh) 2002-03-13
JP2002537242A (ja) 2002-11-05
PE20001499A1 (es) 2001-01-12
IL192666A0 (en) 2009-02-11
KR20010093281A (ko) 2001-10-27
NZ513529A (en) 2003-10-31
BRPI0008228B1 (pt) 2016-08-23
HUP0105364A2 (hu) 2002-05-29
AR082579A2 (es) 2012-12-19
US20140056974A1 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
CN100367930C (zh) 可自发分散的n-苯甲酰基-星形孢菌素组合物
AU765935B2 (en) Substantially oil-free cyclosporin compositions
JP2003500454A5 (https=)
JP6259288B2 (ja) 医薬組成物
AU755134B2 (en) Microemulsion preconcentrates containing a piperidine substance P antagonist
MXPA01008293A (en) Spontaneously dispersible n-benzoyl staurosporine compositions
HK1035137B (en) Microemulsion preconcentrates containing a piperidine substance p antagonist

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1045807

Country of ref document: HK

C56 Change in the name or address of the patentee

Owner name: NOVARTIS CO., LTD.

Free format text: FORMER NAME: NOVARTIS AG

CP01 Change in the name or title of a patent holder

Address after: Basel

Patentee after: Novartis Ag

Address before: Basel

Patentee before: Novartis AG

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20080213